Detalhe da pesquisa
1.
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
Circulation
; 145(3): 184-193, 2022 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779658
2.
Interleukin-6, infection and cardiovascular outcomes in acute heart failure: Findings from the EDIFICA registry.
Cytokine
; 160: 156053, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36179534
3.
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
Lancet
; 396(10244): 121-128, 2020 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32446323
4.
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled.
Circulation
; 147(1): 101-104, 2023 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36342827
5.
Histone deacetylase inhibitors for cardiovascular conditions and healthy longevity.
Lancet Healthy Longev
; 2(6): e371-e379, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36098145
6.
Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives.
Eur Heart J Cardiovasc Pharmacother
; 3(1): 48-57, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27530337
7.
To the Editor--Diabetes and sudden death: Let's assess the absolute risk increase rather than the proportional risk from sudden cardiac death!
Heart Rhythm
; 12(11): e138, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26272526